Arthritis Clinical Trials in Tampa
View 64 new treatments for Arthritis in Tampa, FL, and nearby areas, such as Clearwater, Lakeland and St. Petersburg. Every day, Power helps hundreds of arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Upadacitinib vs Adalimumab for Rheumatoid Arthritis
AbbVie Clinic, Tampa + 8 more
This trial is testing two medications, upadacitinib (a daily pill) and adalimumab (an injection), for adults with rheumatoid arthritis who haven't responded to other treatments. The study aims to see which drug is safer and more effective. Both medications work by reducing inflammation through different mechanisms in the immune system. Adalimumab, an injection, has been extensively studied and used for treating rheumatoid arthritis, showing significant improvements in patients who have not responded to other treatments.Show More
Verified
Recruiting
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director
QUC398 for Knee Osteoarthritis
Novartis Clinic, Tampa + 3 more
This trial is testing a new treatment called QUC398 to see if it can help people with knee osteoarthritis. The study will check if QUC398 can reduce knee pain and protect the cartilage in the knee. Researchers also want to make sure it is safe and well-tolerated.Show More
Verified
Recruiting
Phase 2
Est. 3 - 12 Weeks
Novartis Pharmaceuticals
Study Director
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, Tampa + 3 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Clearwater + 4 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
COVID-19 Vaccines for Rheumatic Diseases
Research Clinic, Riverview + 1 more
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Baricitinib for Rheumatoid Arthritis
Eli Lilly Clinic, Riverview + 6 more
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Clearwater + 1 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
David W Romness, MD
Principal Investigator
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Palm Harbor + 2 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
UCB Cares
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Clearwater + 2 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Tampa + 9 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
AbbVie Inc.
Study Director
Page 1 of 6
Frequently Asked Questions
Explore related conditions